KLRG1

Study Details Immune Cells Vital to Success of Vaccines against Coronavirus

Retrieved on: 
Thursday, September 21, 2023

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- A study has revealed new details about a key population of immune system cells critical to successful vaccination against the pandemic virus, SARS-CoV-2.

Key Points: 
  • A subset of T cells, labeled with the surface protein CD8, produce molecules that directly kill infected cells.
  • B cells produce antibody proteins that neutralize and label infected cells for removal from the body.
  • The mRNA vaccines deployed against COVID-19 were based on RNA, a genetic material used to encode the spike protein that the virus needs to attach to human cells.
  • "Although our study looks at mRNA vaccination against coronavirus, the antigen-specific CD8+ T cell subpopulations we uncover represent key features of immune responses more broadly, and may help us to study T cells in other disease settings."

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

Retrieved on: 
Thursday, August 17, 2023

Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the successful close of an oversubscribed $155 million Series B financing co-led by Redmile Group and Bain Capital Life Sciences.

Key Points: 
  • Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the successful close of an oversubscribed $155 million Series B financing co-led by Redmile Group and Bain Capital Life Sciences.
  • “Support from such a strong group of investors will allow us to complete our development programs in diseases where there are few to no treatment options available,” said Alex Martin, Chief Executive Officer of Abcuro.
  • “We are very motivated by the patients we serve and are excited by the clinical data we’ve seen to date.
  • “IBM, like other autoimmune diseases, is progressive and devastating for patients.

Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

Retrieved on: 
Wednesday, May 31, 2023

Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM).

Key Points: 
  • Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the sentinel cohort of a Phase 2/3 study of ABC008 for the treatment of inclusion body myositis (IBM).
  • The company also announced that they expect to have review of the sentinel cohort safety data by an independent Data Safety Monitoring Board (DSMB) by the end of this year.
  • The Phase 2/3 study is designed as a randomized, double-blind, placebo-controlled multicenter study.
  • “The selectivity of ABC008 offers a distinct advantage over broad T cell depleters for the potential treatment of autoimmune conditions like IBM.

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

Retrieved on: 
Friday, November 5, 2021

ABC008, a first-in-class monoclonal antibody, binds KLRG1 (killer cell lectin-like receptor G1), a marker for highly cytotoxic T cells.

Key Points: 
  • ABC008, a first-in-class monoclonal antibody, binds KLRG1 (killer cell lectin-like receptor G1), a marker for highly cytotoxic T cells.
  • In the first cohort of individuals with IBM, selective and sustained depletion of highly cytotoxic T cells coincided with early signals of functional improvement.
  • The single dose resulted in sustained depletion of highly cytotoxic T cells for at least two months, while sparing regulatory T cells (Tregs).
  • We are extremely encouraged and excited by these early clinical results from our study, said Niti Goel, M.D., Chief Medical Officer of Abcuro.

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress

Retrieved on: 
Wednesday, October 6, 2021

The flagship indication for ABC008 is inclusion body myositis (IBM), an autoimmune disease in which highly differentiated cytotoxic T cells that express KLRG1 attack muscle tissue.

Key Points: 
  • The flagship indication for ABC008 is inclusion body myositis (IBM), an autoimmune disease in which highly differentiated cytotoxic T cells that express KLRG1 attack muscle tissue.
  • The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABC008 for the treatment of IBM.
  • Muscle tissue from patients with IBM show the presence of highly differentiated cytotoxic T cells that express KLRG1.
  • Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise depletion of highly cytotoxic T cells.